spacer
home > ebr > autumn 2009 > the biosimilars market
PUBLICATIONS
European Biopharmaceutical Review

The Biosimilars Market

 

Biosimilars, or ‘follow-on biologics’ as they are known in the US, provide access to affordable and effective medicines to patients around the world. Although the regulatory pathway put forward by the European Medicines Agency (EMEA) has facilitated the launch of a number of biosimilars, the market is still considered to be in a nascent stage. Estimates from IMS Health suggest that products worth $25 billion are expected to go off-patent by 2017, creating a significant opportunity for biosimilar players.

This article aims to set out the key challenges facing biosimilar market participants, in addition to various factors driving and restraining market growth. It also provides an overview of the competitive landscape of the current biosimilars industry and market trends.

THE ROLE OF BIOSIMILARS IN CONTROLLING PHARMACEUTICAL EXPENDITURE

One of the biggest problems facing developed economies around the world is the increase in per capita healthcare spending, which surpasses per capita income in several cases. As Figure 1 indicates, this trend is unsustainable in the long-run, and most governments have begun to take measures to ensure that spending growth falls in line with per capita income. Pharmaceutical expenditure, which is a critical component of healthcare budgets across the world, is being widely recognised as an area that needs to be controlled. This is precisely where generics and biosimilars have a crucial role to play. According to the European Generic medicines Association (EGA), generic medicines have made major contributions to affordable and accessible healthcare for over 20 years, saving the EU an estimated €20 billion annually. by 2017, creating a significant opportunity for biosimilar players.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sumanth Kambhammettu is a Programme Leader with the European Healthcare Practice of Frost & Sullivan. He focuses on analysing trends in the pharmaceutical and biotechnology markets. He has worked on various consulting projects and research reports in the areas of CNS, women’s health, cardiovascular therapeutics, generics and biosimilars, pricing and reimbursement issues, speciality pharma, stem cells, contract manufacturing organisations and several other issue-based topics. In addition, he is a regular contributor of articles on market related issues to leading industry journals. Prior to joining Frost & Sullivan, Sumanth had worked as a marketing executive with Baxter India’s renal division. Sumanth holds a B-Pharm (Hons) from the Birla Institute of Technology & Sciences (BITS), Pilani.
spacer
Sumanth Kambhammettu
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bruker Presents High-Value Life Science, Materials Research and Applied Market Solutions at Analytica 2022

MUNICH, Germany - June 21, 2022: Bruker Corporation (Nasdaq: BRKR) this week displays its high-value scientific instrumentation, software and integrated solutions for applications in materials and energy research, biopharmaceuticals, applied markets, as well as life science and translational research at Analytica 2022.
More info >>

White Papers

Quality of Steel

Natoli Engineering Company, Inc.

Steel quality is the summation of how well a steel meets its specified chemistry, the cleanliness of the steel or degree to which it is free of impurities or inclusion, homogeneity of the microstructure, grain/carbide size and in some instances if it meets the mechanical requirements for that particular steel. In the design and manufacture of tablet compression tooling, nothing is more important than the quality of the materials being used. The best manufacturing principals maintaining the tightest tolerances will result in tool failure if the initial material quality is poor. Material quality is the fundamental building block upon which all successive value added steps are laid. The majority of all tablet compression tooling is produced from steel and steel quality is the subject of this article.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement